Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818025 | 1.00 | NUDT1 (0.47) | NUDT1PSMB5LMNASMN1; SMN2MCOLN3 | |
| SCHEMBL8574705 | 0.89 | MAOB (0.42) | NUDT1PSMB5LMNASMN1; SMN2MCOLN3 | |
| SCHEMBL2799978 | 0.89 | NUDT1 (0.51) | NUDT1PSMB5LMNAKDM4EESR2 | |
| SCHEMBL9326316 | 0.85 | ALDH1A1 (0.54) | NUDT1KDM4EESR2ALDH1A1HSD17B10 | |
| SCHEMBL22517389 | 0.83 | ALDH1A1 (0.52) | ESR2ALDH1A1HSD17B10TP53CYP3A4 | |
| SCHEMBL3791658 | 0.83 | ACHE (0.42) | LMNASMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL25932259 | 0.83 | NUDT1 (0.47) | NUDT1PSMB5SMN1; SMN2KDM4EESR2 | |
| SCHEMBL3788483 | 0.82 | NPC1 (0.48) | SMN1; SMN2KDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL22554778 | 0.82 | ALDH1A1 (0.50) | LMNAKDM4EESR2ALDH1A1HSD17B10 | |
| Hydrogen Peroxide SCHEMBL28323910 | 0.81 | KDM4E (0.48) | LMNAKDM4EALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659245-A | Linear medium-low density vinyl polymer with polar groups | 中国石油天然气股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-10825999-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-11-03 | — | — | US | disclosed |
| US-10825999-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-11-03 | — | — | US | disclosed |
| EP-3231808-B1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZING, AND METHOD FOR OLEFIN OLIGOMERIZATION USING SAME | LG CHEMICAL LTD (KR) | 2020-07-22 | — | — | EP | disclosed |
| CN-107207545-B | Ligand compound, oligomerization catalyst system and olefin oligomerization method using the same | LG化学株式会社 | 2020-07-07 | — | — | CN | disclosed |
| US-10344044-B2 | Ligand compound, catalyst system for oligomerization, and method for olefin oligomerization using the same | LG CHEM, LTD. (KR) | 2019-07-09 | — | — | US | disclosed |
| US-20180261781-A1 | OGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-09-13 | — | — | US | disclosed |
| US-20170369515-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME (As Amended) | LG CHEM, LTD. (KR) | 2017-12-28 | — | — | US | disclosed |
| EP-3231808-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZING, AND METHOD FOR OLEFIN OLIGOMERIZATION USING SAME | LG Chem, Ltd. (KR) | 2017-10-18 | — | — | EP | disclosed |
| CN-107207545-A | ligand compound, oligomerization catalyst system and olefin oligomerization method using the same | LG化学株式会社 | 2017-09-26 | — | — | CN | disclosed |
| US-8383545-B2 | Strategies, linkers and coordination polymers for high-performance sorbents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090062498-A1 | NOVEL STRATEGIES, LINKERS AND COORDINATION POLYMERS FOR HIGH-PERFORMANCE SORBENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-03-05 | — | — | US | disclosed |
| EP-0946552-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6420567-B1 | PRODRUGS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| EP-0946552-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369515-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME (As Amended) | OXER1, NOTUM, OSTC | NUDT1 393/4885PSMB5 1650/4885LMNA 4497/4885 |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | NUDT1 3160/4885PSMB5 2687/4885LMNA 3207/4885 |
| US-20180261781-A1 | OGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | OCIAD1, OGFOD1, ODC1 | NUDT1 1517/4885PSMB5 3393/4885LMNA 4058/4885 |
| US-20090062498-A1 | NOVEL STRATEGIES, LINKERS AND COORDINATION POLYMERS FOR HIGH-PERFORMANCE SORBENTS | ILK, TIMCC, EPCAM | NUDT1 3291/4885PSMB5 4108/4885LMNA 4273/4885 |
| US-10825999-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | NUDT1 2308/4885PSMB5 3454/4885LMNA 4476/4885 |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | NUDT1 3160/4885PSMB5 2687/4885LMNA 3207/4885 |
| US-10344044-B2 | Ligand compound, catalyst system for oligomerization, and method for olefin oligomerization using the same | OXER1, OSTC, OCIAD1 | NUDT1 220/4885PSMB5 2279/4885LMNA 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.